Migraine headaches afflict approximately 26 million people in the United States. This disorder causes incapacitating and disabling headaches, predominantly in women leading to reduced work productivity and quality of life in addition to disrupted family and spousal relationships. In addition, disability caused by physical symptoms of head pain, nausea, vomiting, malaise, photophobia and phonophobia is accompanied by cognitive disability. Patients report cognitive symptoms of mental “clouding”, difficulties in thinking, attention, concentration, memory, judgment, calculation and problem solving. These symptoms lead to a neurobehavioral disorder with frustration, impatience and irritability lasting for hours after the headache subsides. The first report of cognitive testing among migraineurs during the headache phase, of which we are aware, was by Black et al in 1997 presented at the annual meeting of the American Association for the Study of Headache. Thirty migraineurs were interviewed during migraine intervals in the clinic or by telephone. Temporary impairments of immediate and sustained attention and verbal learning accompanying headache intervals were revealed. In 1999 Mulder et al reported self-administration of the Neurobehavioral Evaluation System (NES2) among migraineurs with and without aura when headache-free, as well as 30 hours after headache had subsided following a night’s sleep. Migraineurs with aura showed slower response times, but test results were not measurably altered 30 hours after recovery from headache and nocturnal sleep. Another study by John Meyer et al published in 2000 reported cognitive decline during a migraine attack that was relieved by sleep and serotonin agonists. Cognitive function has also been examined during migraine, before and after treatment with a triptan (Sumatriptan nasal spray, 20mg) showing that treatment with a triptan medication restored migraine-related cognitive function and clinical disability.